Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned an average recommendation of “Hold” from the eight ratings firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $20.00.

Several research analysts have recently issued reports on the stock. Janney Montgomery Scott reiterated a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, June 12th. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BidaskClub downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. HC Wainwright started coverage on shares of Collegium Pharmaceutical in a research note on Monday, September 11th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, ValuEngine upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd.

TRADEMARK VIOLATION NOTICE: “Analysts Set Collegium Pharmaceutical, Inc. (COLL) PT at $21.40” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/23/analysts-set-collegium-pharmaceutical-inc-coll-pt-at-21-40.html.

Collegium Pharmaceutical (NASDAQ:COLL) traded up 2.49% during trading on Wednesday, hitting $10.31. 256,806 shares of the stock were exchanged. The stock has a 50 day moving average of $10.41 and a 200-day moving average of $10.41. The stock’s market cap is $304.83 million. Collegium Pharmaceutical has a 52 week low of $9.68 and a 52 week high of $20.55.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $4.07 million. Equities analysts expect that Collegium Pharmaceutical will post ($3.00) EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of COLL. Teachers Advisors LLC lifted its position in Collegium Pharmaceutical by 18.1% during the fourth quarter. Teachers Advisors LLC now owns 25,437 shares of the specialty pharmaceutical company’s stock valued at $396,000 after purchasing an additional 3,892 shares during the period. Nationwide Fund Advisors lifted its position in Collegium Pharmaceutical by 16.4% during the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 1,422 shares during the period. Wells Fargo & Company MN lifted its position in Collegium Pharmaceutical by 404.1% during the first quarter. Wells Fargo & Company MN now owns 86,776 shares of the specialty pharmaceutical company’s stock valued at $873,000 after purchasing an additional 69,563 shares during the period. Bank of New York Mellon Corp lifted its position in Collegium Pharmaceutical by 6.1% during the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock valued at $656,000 after purchasing an additional 3,775 shares during the period. Finally, Trexquant Investment LP bought a new position in Collegium Pharmaceutical during the first quarter valued at approximately $259,000. Institutional investors own 83.04% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.